The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global multiple sclerosis therapies market size reached US$ 24.5 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 32.3 Billion by 2027, exhibiting a growth rate (CAGR) of 4.61% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.
Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.
The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.
IMARC Group provides an analysis of the key trends in each sub-segment of the global multiple sclerosis therapies market report, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug, drug type, route of administration and distribution channel.
Breakup by Drug:
Breakup by Drug Type:
Breakup by Route of Administration:
Breakup by Distribution Channel:
Breakup by Region:
The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Drug, Drug Type, Route of Administration, Distribution Channel, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at